Difference between revisions of "Bone sarcoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov")
Line 19: Line 19:
 
=Guidelines=
 
=Guidelines=
 
==[http://www.esmo.org/ ESMO]==
 
==[http://www.esmo.org/ ESMO]==
*[http://annonc.oxfordjournals.org/content/25/suppl_3/iii113.full.pdf+html Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/25210081 PubMed]
+
*[http://annonc.oxfordjournals.org/content/25/suppl_3/iii113.full.pdf+html Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://pubmed.ncbi.nlm.nih.gov/25210081 PubMed]
 
==[https://www.nccn.org/ NCCN]==
 
==[https://www.nccn.org/ NCCN]==
 
*[https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf NCCN Guidelines - Bone Cancer]
 
*[https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf NCCN Guidelines - Bone Cancer]

Revision as of 02:23, 25 February 2020

Section editor
Elizabethdavis2.jpg
Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN

Social-twitter-icon.pngejdavis25
0 regimens on this page
0 variants on this page


Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:

Guidelines

ESMO

NCCN

Chondrosarcoma, all lines of therapy

Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy